Abstract
Background Congenital myocardial hypoplasia affects heart function in congenital heart diseases, but its causes and mechanisms are unclear. Methods: Fetuses with myocardial hypoplasia were examined using echocardiography imaging and genetic testing. The identified pathogenic genes were genetically targeted to validate mechanistic findings. We used stem cells and transgenic mice to understand molecular mechanisms and applied Preimplantation Genetic Testing for monogenic defects to obtain healthy offspring. In addition, 1,300 genetic sequencing records were screened to understand the prevalence of the disease and deepen our understanding of myocardial hypoplasia treatment.
Results This is the first study to link PFKP pathogenic variant to human myocardial hypoplasia. We found that PFKP deficiency decreased embryonic heart glycolysis, resulting in a thinning myocardial wall and impaired cardiac function, attributable to a decline in cardiomyocyte proliferation. The intrauterine supplement with Fructose 1,6-bisphosphate, a direct product of PFKP catalysis, can rescue the main myocardial phenotype of fetal mice. Assisted reproductive technology was used to prevent PFKP pathogenic variant transmission to offspring. Finally, one of the family lines (family 1) obtained a healthy offspring with a normal heart. Conclusions PFKP plays a key role in regulating glycolysis during embryonic cardiac development. Addressing glycolytic defects is crucial for myocardial hypoplasia. We provide new insights that have implications for genetic interventions, prenatal screening, and targeted intervention strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was sponsored by the National Natural Science Foundation of China (No U21A20523 and 82170301 to Yihua He; No. 82200334 to Xiaoyan Hao; No. 82100322 to Tong Yi).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed written consent was obtained from all study participants or their legal guardians, and the study was approved by the Ethics Committee of Beijing Anzhen Hospital of Capital Medical University. The study received approval from the Ethics Committee for Reproductive Research at Peking University Third Hospital.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
